Tesla sold 8,621 cars in China in July, accounting for just 3.9 percent sales of battery electric vehicles in the country, down nearly 70 percent from its 12.6 percent share in June, according to the China Passenger Car Association.
Analyst Gordon Johnson said that Tesla overbuilt Chinese capacity when compared to domestic demand, which will result in further price cuts and margin pressure.
But Tesla investors seemed unfazed by the sales decline, with shares dropping less than 2 percent in early trading Tuesday.
Last month, Tesla exhibited that its declining numbers in China didn't stop it from posting better than expected global sales for the full quarter, according to Wedbush Securities tech analyst Dan Ives. He noted that its numbers in China had not been the best indicator of Tesla's success.
Nonetheless, Ives warned that if Tesla's sales in China don't improve, it could eventually face serious problems.
Meanwhile, the export of Tesla cars built at its Shanghai plant soared to 24,347 for July, compared with 5,017 in June.


Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation
Air Canada Express Plane Collides with Ground Vehicle at LaGuardia Airport
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield
U.S. Oil Prices Slide as Middle East Ceasefire Talks Spark Market Optimism
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion
Suspicious Oil Market Trades Precede Trump's Iran Peace Post by 15 Minutes
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 



